mitomycin

B1-21 cells were particularly sensitive to camptothecin and the PARP inhibitor NU1025, whereas V-C8 cells showed higher sensitivity to etoposide, cisplatin, mitomycin C, and bleomycin. These findings indicate that partial disruption of the BRCA1 RING domain results in a hypomorphic phenotype with impaired homologous recombination, defective checkpoint control, and enhanced genotoxic sensitivity. The isogenic BRCA1 and BRCA2 mutant V79 lines offer a valuable model for dissecting DDR pathway differences and developing mutation-specific therapeutic strategies targeting BRCA-mutant cancers.

P=N/A, N=15, Recruiting, Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital

P=N/A, N=100, Tsinghua Changgung Hospital, Beijing; Beijing Tsinghua Changgung Hospital

P2, N=82, Recruiting, National Cancer Center, Korea | Trial primary completion date: Dec 2025 --> Dec 2027

PG-NE exhibited potent cytotoxic, pro-apoptotic, and antimigratory activities in vitro. Its physicochemical stability and biological activity support its potential use as a chemopreventive or adjunctive agent.

P4, N=36, Not yet recruiting, All India Institute of Medical Sciences, Bhubaneswar

P1, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2031 --> Dec 2034 | Trial primary completion date: Dec 2030 --> Dec 2033

We recently identified that a protein molecule, the amino-terminus region of the dense granule protein 6 (GRA6Nt) of Toxoplasma gondii, selectively activates innate expressions of IFN-γ and IL-18 and functions as a powerful adjuvant when used in immunization with nonreplicable (treated with mitomycin C or irradiated) MC38 CRC cells to potently activate the cytotoxic activity and IFN-γ production of CD8+ T cells against cancer cells...In contrast to the two nucleotide- or deoxynucleotide-based Toll-like receptor agonists currently being used as adjuvants in cancer immunotherapy in clinical settings, GRA6Nt is a protein molecule. Thus, the rGRA6Nt protein adjuvant provides a new pathway in cancer immunotherapy to effectively activate the protective CD8+ T cells specific for the individual's cancer cells to prevent the recurrence of surgically resected CRC in patients.

P1, N=24, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute

P1/2, N=50, Recruiting, Amsterdam UMC | Not yet recruiting --> Recruiting

Finally, the sensitivity of 5 common drugs (docetaxel, cisplatin, doxorubicin, mitomycin C, and paclitaxel) was evaluated using an OS-CSC-related prognostic model. In conclusion, an OS-CSC-related prognostic model based on 5 genes (PLK2, CACNA1C, PENK, NR0B1, and HNF4A) was constructed using bioinformatics analysis, which may provide new insights into the treatment and evaluation of OC.

P3, N=236, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.